COMMUNIQUÉS West-GlobeNewswire

Ceapro Inc. Announces Three Abstracts Selected for Oral Presentation at the 17th European Meeting on Supercritical Fluids (EMSF 2019)
26/02/2019
- Important research findings from collaboration with University of Alberta demonstrating potential of Ceapro’s unique enabling PGX technology to produce innovative delivery systems - EDMONTON, Alberta, Feb. 26, 2019 ( [...]
Chimerix to Announce Fourth Quarter and Full Year 2018 Financial Results on March 5, 2019
26/02/2019
DURHAM, N.C., Feb. 26, 2019 (GLOBE NEWSWIRE) -- Chimerix, Inc. (Nasdaq: CMRX), a biopharmaceutical company developing novel antivirals to address life-threatening viral infections, today announced that it will host a [...]
Q BioMed's Autism Spectrum Disorder Drug Development Program Featured in February Issue of Leading Pharma/Biotech Newspaper
26/02/2019
Groundbreaking pediatric non-verbal disorder treatment QBM-001 presented to over 30,000 drug discovery professionals through print edition of DDN News NEW YORK, Feb. 26, 2019 (GLOBE NEWSWIRE) -- Q BioMed Inc. ( QBIO ), [...]
BioSig Announces Expansion of Engineering Team
26/02/2019
New hires to drive R&D and manufacturing efforts Santa Monica, CA, Feb. 26, 2019 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM), a medical device company developing a proprietary biomedical signal [...]
Transactions in relation to share buyback program
26/02/2019
Acting under its share buyback authorization, the GN Store Nord Board of Directors initiated a share buyback program on May 2, 2018, in accordance with article 5 of the regulation (EU) no. 596/2014 of 16 April 2014 on [...]
Ocutrx Vision Technologies dévoile le concept révolutionnaire Oculenz AR à connectivité cellulaire avec le design des lunettes de poursuite oculaire
26/02/2019
La nouvelle conception esthétique offre une technologie et des fonctionnalités sans précédent dans l'industrie AR Wear BARCELONE, Espagne, 26 févr. 2019 (GLOBE NEWSWIRE) -- Ocutrx Vision Technologies, LLC , fabricant de [...]
How Augmented Reality is Transforming the Fashion Industry -- CFN Media
26/02/2019
SEATTLE, Feb. 26, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- CFN Media Group (“CFN Media”), the leading agency and financial media network dedicated to the North American cannabis industry, announces publication of an [...]
FSD Pharma's Investments in Cutting-Edge Tech Could Pay Big Dividends -- CFN Media
26/02/2019
SEATTLE, Feb. 26, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- CFN Media Group (“CFN Media”), the leading agency and financial media network dedicated to the North American cannabis industry, announces publication of an [...]
New data shows ALK’s house dust mite SLIT-tablet significantly improves quality of sleep for allergic rhinitis patients
26/02/2019
Approximately 9 out of 10 trial subjects with 'moderately or severely affected sleep' saw an improvement following treatment with ALK’s HDM SLIT-tablet. The results were revealed by a post-hoc analysis of sleep-specific [...]
Verona Pharma Reports Financial Results for Full Year Ended December 31, 2018 and Provides Clinical Development Update
26/02/2019
LONDON, Feb. 26, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) (Verona Pharma), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for [...]
ESPERITE (ESP) announces private placement of convertible loan notes to the European Select Growth Opportunities Fund
26/02/2019
Amsterdam, The Netherlands – 26 February 2019 Esperite N.V. (Euronext: ESP, “ Esperite ”) announces today a EUR 280,000 private placement of 28 convertible notes with a principal amount of EUR 10,000 each (the “ Notes [...]
Biocartis Group NV: Biocartis Places Its 1,000th Idylla(TM) Instrument with Geisinger in US
26/02/2019
PRESS RELEASE: 26 February 2019, 07:00 CET Biocartis Places Its 1,000 th Idylla(TM) Instrument with Geisinger in US Mechelen, Belgium, 26 February 2019 - Biocartis Group NV (the 'Company' or 'Biocartis'), an innovative [...]
IBA DÉCLARATION INTERMÉDIAIRE
26/02/2019
IBA Déclaration Intermédiaire Retour à la profitabilité au deuxième semestre 2018 Louvain-la-Neuve, Belgique, 26 février 2019 – IBA ( Ion Beam Applications SA ), le premier fournisseur mondial de solutions de [...]
IBA Trading Update
26/02/2019
IBA Trading Update Return to net profitability in H2 Louvain-La-Neuve, Belgium, February 26, 2019 - IBA (Ion Beam Applications S.A., EURONEXT), the world’s leading provider of proton therapy solutions for the treatment [...]
Dr. Amir Bajoghli Recognized as Top Doctor in Dermatology by Northern Virginia Magazine
26/02/2019
MCLEAN, Va., Feb. 25, 2019 (GLOBE NEWSWIRE) -- Dr. Bajoghli of the Skin and Laser Surgery Center has once more been awarded recognition as a Top Doctor in Dermatology and MOHS Surgery for 2019, by Northern Virginia [...]
Novartis issues summary financial information for the Alcon eye care business ahead of shareholder vote on proposed spin-off
25/02/2019
Basel, February 25, 2019 - Novartis today published certain key financial information for the Alcon eye care business covering the full year 2018 ahead of a vote on the proposed 100% spin-off of Alcon at the Novartis [...]
Sanofi : Sanofi and Regeneron strongly disagree with verdict upholding three of five Amgen U.S. patent claims relating to PCSK9 antibodies
25/02/2019
Sanofi and Regeneron strongly disagree with verdict upholding three of five Amgen U.S. patent claims relating to PCSK9 antibodies Praluent ® (alirocumab) continues to be available in the U.S. PARIS and TARRYTOWN, NY - [...]
Sanofi : Sanofi et Regeneron sont en profond désaccord avec le verdict confirmant trois des cinq brevets américains d'Amgen relatifs aux anticorps PCSK9
25/02/2019
Sanofi et Regeneron sont en profond désaccord avec le verdict confirmant trois des cinq brevets américains d'Amgen relatifs aux anticorps PCSK9 Praluent ® (alirocumab) continue d'être disponible aux Etats-Unis Paris et [...]
MacroGenics Announces Participation in SVB Leerink Global Healthcare Conference
25/02/2019
ROCKVILLE, MD, Feb. 25, 2019 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for [...]

Pages